Glaukos Corporation announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for iDose®? TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The new J-code foriDose TR, J7355, is set to become effective July 1, 2024.

It is expected to increase patient access in the U.S. and has been published here on the CMS website. J-codes are used by U.S. government and commercial payers, as well as surgeons, to streamline the billing and reimbursement process for procedural pharmaceuticals administered by a healthcare professional, such as iDose TR, along with other certain treatments. In addition to the J-code, on March 21, 2024, CMS issued its April 2024 Update of the Hospital Outpatient Prospective Payment System (OPPS) transmittal published here on the CMS website, in which it assigned the CT codes that are designed to be used to cover the procedural component of iDose TR, 0660T and 0661T, to ambululatory payment classification (APC) 5492 (Level 2 Intraocular Procedures), effective April 1, 2024.

iDose TR is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.